EP0143949A1 Expired / Lapsed EP ⏱️ 0.0 years remaining

Pharmaceutical composition containing urokinase

Assignee: Terumo Corp

•

Filing: 1984-10-09

•

Granted: —

•

Expires: 2004-10-09

📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A pharmaceutical composition containing urokinase and a physiological absorption enhancer comprising higher fatty acids, a polyalkylene glycol and calcium is disclosed. Whereas urokinase which is decomposed and inactivated in the stomach and is poorly absorbed from the intestinal tract cannot be orally administered, it can be orally administered in the form of the present composition by applying enteric coating, because urokinase in the composition is highly absorbable from the intestinal tract. It is desirable in the present composition in view of the stability and sustained absorbability that urokinase is contained in said composition in the form of a liposome preparation in which the urokinase is incorporated in voids of the liposome. The components are incorporated in the present composition at a ratio of 0.01 - 2 mg. of the higher fatty acid, 0.01 - 5 mg. of the polyalkylene glycol and 0.0001 - 0.1 mg. of the calcium per 100 units of urokinase. The present composition is satisfactory for use as a thrombolytic agent.

Inventors

👤 Fujio Nakagame
👤 Haruo Honda
👤 Teppei Maruyama
👤 Noriko Saito
👤 Tomoaki Kimoto

Bibliographic Details

Application Number —

Jurisdiction EP

Data Source google_patents

Last Synchronized 2026-10-30 08:41

CPC Classifications

A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1277; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K9/20; A61K9/2004; A61K9/2013; A61K9/2022; A61K9/2031; A61K9/48; A61K9/4841; A61K9/4858; A61K9/4866; A61K9/4891

Claims Analysis

Total Claims: 10

Claim 1

Independent Claim 34 words

A pharmaceutical composition containing urokinase comprising a therapeutically effective amount of urokinase and an effective amount of physiological absorption enhancer, said enhancer comprising one or more higher fatty acids, a polyalkylene glycol and calcium.

Claim 2

Dependent Claim 34 words

Claim 3

Dependent Claim 20 words

A pharmaceutical composition containing urokinase according to Claim 1 wherein the higher fatty acid contains 10 - 20 carbon atoms.

Claim 4

Dependent Claim 26 words

A pharmaceutical composition containing urokinase according to Claim 2 wherein the higher fatty acid contains 1 - 4 double bonds and 18 - 20 carbon atoms.

Claim 5

Dependent Claim 17 words

A pharmaceutical composition containing urokinase according to Claim 3 wherein the higher fatty acid is oleic acid.

Claim 6

Dependent Claim 17 words

A pharmaceutical composition containing urokinase according to Claim 3 wherein the polyalkylene glycol is a polyethylene glycol.

Claim 7

Dependent Claim 19 words

A pharmaceutical composition containing urokinase according to Claims 1 - 5 wherein the urokinase is an urokinase-carrying liposome preparation.

Claim 8

Dependent Claim 31 words

A pharmaceutical composition containing urokinase according to Claim 6 wherein the urokinase-carrying liposome preparation is a liposome preparation the membrane material of which contains a lipid and a higher fatty acid.

Claim 9

Dependent Claim 19 words

.8. A pharmaceutical composition containing urokinase according to Claim 6 or 7 wherein the lipid is a hydrogenated lecithine.

Claim 10

Dependent Claim 42 words

A pharmaceutical composition containing urokinase according to Claim 1 which contains 0.01 - 2 mg. of the higher fatty acid, 0.01 - 5 mg. of the polyalkylene glycol and 0.0001 - 0.1 mg. of the calcium per 100 units of the urokinase.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Maintenance schedule is calculated for granted US utility patents.

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag

Select Category

Notes (Optional)